Meningococcal Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Conjugate, Polysaccharide, Combination, Others), By Age Group (Infant, Children & Adult), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 4.38 Billion
CAGR (2026-2031)	5.91%
Fastest Growing Segment	Combination
Largest Market	North America
Market Size (2031)	USD 6.18 Billion

Market Overview

The Global Meningococcal Vaccines Market will grow from USD 4.38 Billion in 2025 to USD 6.18 Billion by 2031 at a 5.91% CAGR. Meningococcal vaccines are biological preparations designed to establish immunity against Neisseria meningitidis bacteria, thereby preventing invasive diseases such as meningitis and septicemia. The global market is fundamentally driven by the inclusion of these vaccines in national immunization schedules and rigorous regulatory mandates requiring vaccination for travelers to endemic regions, particularly for Hajj and Umrah pilgrims. Additionally, the increasing implementation of government-funded catch-up campaigns for adolescents and the expanding commercial uptake of Serogroup B vaccines in private sectors serve as primary catalysts supporting sustained revenue growth.

However, a significant challenge impeding broader market expansion is the high cost of vaccine development and the complex cold-chain logistics required for distribution in low-income regions. This economic barrier limits accessibility despite the clear public health necessity driven by rising infection rates. According to the Centers for Disease Control and Prevention, in 2024, the United States reported 503 confirmed and probable cases of meningococcal disease, representing the highest annual number of cases recorded since 2013. This statistic highlights the critical demand for vaccines even as supply chain and pricing hurdles complicate global market penetration.

Key Market Drivers

The recent surge in invasive meningococcal disease outbreaks across Europe and Africa acts as a primary market accelerator, compelling governments to reinforce surveillance and emergency vaccination protocols. This resurgence is particularly evident in regions previously considering the disease under control, necessitating the immediate procurement of vaccines to curb transmission. For instance, according to the UK Health Security Agency, November 2025, confirmed cases of invasive meningococcal disease in England rose to 378 in the 2024-25 period, up from 340 cases the previous year. Such epidemiological shifts are driving the expansion of national immunization schedules and catch-up campaigns, directly translating to increased vaccine order volumes as public health authorities prioritize containment.

Simultaneously, the market is being reshaped by the distribution of next-generation multivalent conjugate vaccines, which offer broader protection against multiple serogroups in a single dose. These advancements streamline logistics for mass immunization drives, particularly in high-risk zones where cold-chain management is difficult. A notable development occurred when, according to Gavi, the Vaccine Alliance, April 2025, Nigeria received over one million doses of the new pentavalent meningococcal conjugate vaccine (Men5CV) to combat a severe outbreak. This shift toward more comprehensive formulations is reflected in the financial performance of major manufacturers, as broader coverage stimulates commercial uptake. According to GSK, October 2025, sales of its meningitis vaccines reached £0.5 billion in the third quarter of 2025, representing a 5% increase driven by strong international demand.

Download Free Sample Report

Key Market Challenges

The high cost of vaccine development combined with the logistical complexity of maintaining cold-chain integrity creates a substantial barrier to the expansion of the Global Meningococcal Vaccines Market. Manufacturers incur significant financial burdens during the research and production phases, which necessitates pricing strategies that are often incompatible with the limited healthcare budgets of developing nations. This economic disconnect is compounded by the requirement for strict temperature controls during transport, which renders distribution unfeasible in regions lacking reliable infrastructure. Consequently, the market struggles to access the high-demand populations in Sub-Saharan Africa, limiting the commercial viability of these essential products to wealthier, lower-incidence territories.

This inability to establish affordable, routine supply chains forces the market to rely heavily on reactive, donor-funded emergency mechanisms rather than sustainable commercial growth. The prevalence of this reactive model is evident in recent operational data. According to Gavi, the Vaccine Alliance, by the end of 2024, the multivalent meningococcal vaccine emergency stockpile was accessed 68 times by 16 countries, necessitating the shipment of over 34.4 million doses to address outbreaks. This statistic underscores how financial and logistical hurdles effectively confine market activity to sporadic emergency responses, thereby preventing the transition to a broader, more stable revenue model.

Key Market Trends

The Transition to Pentavalent MenABCWY Combination Vaccines is altering the commercial landscape by consolidating protection against five serogroups into a single regimen, thereby addressing low adherence to multi-injection schedules in adolescents. This trend is particularly prominent in developed markets like the United States, where pharmaceutical leaders are securing regulatory milestones for formulations that combine standard MenACWY conjugates with Serogroup B components. A defining moment in this shift occurred when, according to GSK, February 2025, the US Food and Drug Administration (FDA) approved Penmenvy, a novel pentavalent vaccine, for use in individuals aged 10 through 25 years. By reducing the number of required shots, these combination products are expected to significantly improve coverage rates for Serogroup B, which has historically lagged behind other serogroups due to the complexity of separate administration protocols.

Simultaneously, the Integration of Serogroup B Vaccines into National Immunization Schedules marks a critical policy evolution, moving these products from private-market commodities to government-mandated essentials. Health authorities in Europe are increasingly prioritizing universal coverage for infants to mitigate the severe sequelae of invasive meningococcal disease, effectively guaranteeing market volume through public procurement. This policy shift was exemplified when, according to the Ministry of Health (France), January 2025, vaccination against meningococcal serogroup B became mandatory for all infants, necessitating a standardized schedule with doses administered at 3, 5, and 12 months. Such legislative updates compel manufacturers to align their supply chains with national tenders, ensuring stable demand while removing the financial barriers that previously restricted access to these specialized vaccines for high-risk pediatric populations.

Segmental Insights

The Combination segment represents the fastest-growing category in the Global Meningococcal Vaccines Market due to the rising adoption of unified immunization solutions. This growth is largely driven by the development of pentavalent vaccines which consolidate protection against multiple serogroups into a single administration. Regulatory milestones, such as approvals by the U.S. FDA, have validated the efficacy of these formulations, encouraging wider uptake among healthcare providers. By reducing the injection burden and simplifying complex vaccination schedules, combination vaccines significantly enhance patient compliance, thereby fueling the rapid expansion of this segment.

Regional Insights

North America holds a dominant position in the global meningococcal vaccines market due to favorable government initiatives and extensive immunization coverage. The region benefits from established healthcare infrastructure and proactive recommendations by the U.S. Centers for Disease Control and Prevention regarding adolescent vaccination schedules. Furthermore, the presence of key market players and high healthcare expenditure facilitates wide accessibility to preventive treatments. Continuous product approvals by the U.S. Food and Drug Administration also strengthen market growth, ensuring a steady supply of vaccines to meet public health requirements across the region.

Recent Developments

• In May 2025, Sanofi obtained approval from the U.S. Food and Drug Administration to expand the indication of its meningococcal (Groups A, C, Y, W) conjugate vaccine, MenQuadfi, to include infants aged 6 weeks to 23 months. This regulatory decision made the product the only quadrivalent meningococcal conjugate vaccine available in the United States with no upper age limit, allowing healthcare providers to offer protection to the youngest and most vulnerable population. The expanded approval was supported by clinical data demonstrating the vaccine's safety and effectiveness in eliciting an immune response in infants against the four targeted serogroups.
• In February 2025, GSK announced that the U.S. Food and Drug Administration approved Penmenvy, its 5-in-1 meningococcal ABCWY vaccine, for use in individuals aged 10 through 25 years. This approval introduced a comprehensive vaccine option to the U.S. market that covers the five major serogroups associated with invasive meningococcal disease. By combining the antigenic components of its two established meningococcal vaccines into a single formula, the company aimed to streamline the immunization schedule and improve vaccination compliance among adolescents and young adults by reducing the number of required injections.
• In November 2024, Pfizer received marketing authorization from the European Commission for its pentavalent meningococcal vaccine, Penbraya, for the active immunization of individuals 10 years of age and older. This regulatory approval followed a positive opinion from the Committee for Medicinal Products for Human Use and established the vaccine as a new option in the European Union to help protect adolescents and young adults against the five most common serogroups (A, B, C, W, and Y) that cause invasive meningococcal disease. The decision marked a significant milestone in the company's efforts to consolidate protection against multiple serogroups into a single product.
• In April 2024, the Serum Institute of India and the University of Oxford finalized a License of Technology Agreement to advance the development of a novel chimeric protein-based vaccine targeting Neisseria meningitidis serogroup B. This strategic collaboration aims to produce an accessible and affordable vaccine solution that addresses the limitations of currently available MenB vaccines in terms of efficacy and global coverage. The partnership leverages the manufacturing capabilities of the Serum Institute of India to scale up the production of the candidate, which utilizes four chimeric proteins to provide broad protection against invasive meningococcal disease.

Key Market Players

• Sanofi S.A.
• Merck & Co., Inc.
• GlaxoSmithKline plc
• Serum Institute of India Pvt. Ltd.
• Pfizer, Inc.
• Walwax Biotechnology Co., Ltd

By Type	By Age Group	By Region
Conjugate Polysaccharide Combination Others	Infant Children & Adult	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Meningococcal Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Meningococcal Vaccines Market, By Type:

• Conjugate
• Polysaccharide
• Combination
• Others

• Meningococcal Vaccines Market, By Age Group:

• Infant
• Children & Adult

• Meningococcal Vaccines Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE